Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Steven A. J. Salamon, insider at Delcath Systems

Steven A. J. Salamon Insider Information

Director of Delcath Systems
Steven Salamon is a co-founder and Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager established in 2006 (“Rosalind Advisors”). Rosalind Advisors is the investment manager for the Rosalind Funds. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities).

What is Steven A. J. Salamon's net worth?

The estimated net worth of Steven A. J. Salamon is at least $132,702.24 as of May 12th, 2022. Mr. Salamon owns 29,424 shares of Delcath Systems stock worth more than $132,702 as of May 22nd. This net worth approximation does not reflect any other assets that Mr. Salamon may own. Learn More about Steven A. J. Salamon's net worth.

How do I contact Steven A. J. Salamon?

The corporate mailing address for Mr. Salamon and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected] Learn More on Steven A. J. Salamon's contact information.

Has Steven A. J. Salamon been buying or selling shares of Delcath Systems?

Over the course of the past ninety days, Steven A. J. Salamon has bought $39,400.00 of Delcath Systems stock. As far as recent transactions, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on Steven A. J. Salamon's trading history.

Who are Delcath Systems' active insiders?

Delcath Systems' insider roster includes Gerard Michel (CEO), John Purpura (COO), and Steven Salamon (Director). Learn More on Delcath Systems' active insiders.

Are insiders buying or selling shares of Delcath Systems?

During the last twelve months, Delcath Systems insiders bought shares 14 times. They purchased a total of 74,450 shares worth more than $662,387.50. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 41,491 shares worth more than $12,826,112.83. The most recent insider tranaction occured on May, 16th when COO John Purpura bought 3,300 shares worth more than $15,213.00. Insiders at Delcath Systems own 16.8 % of the company. Learn More about insider trades at Delcath Systems.

Information on this page was last updated on 5/16/2022.

Steven A. J. Salamon Insider Trading History at Delcath Systems

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy6,000$4.90$29,400.0029,424View SEC Filing Icon  
4/19/2022Buy1,600$6.25$10,000.00429,100View SEC Filing Icon  
6/30/2021Buy5,500$12.76$70,180.00View SEC Filing Icon  
6/28/2021Buy5,000$11.56$57,800.00View SEC Filing Icon  
6/24/2021Buy4,500$10.90$49,050.00View SEC Filing Icon  
11/13/2020Buy2,000$11.51$23,020.00View SEC Filing Icon  
See Full Table

Steven A. J. Salamon Buying and Selling Activity at Delcath Systems

This chart shows Steven A J Salamon's buying and selling at Delcath Systems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Delcath Systems Company Overview

Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.51
Low: $4.41
High: $4.59

50 Day Range

MA: $5.99
Low: $4.45
High: $6.61

2 Week Range

Now: $4.51
Low: $4.30
High: $13.50

Volume

18,400 shs

Average Volume

31,577 shs

Market Capitalization

$35.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.